Ireland: Prothena raises net US$172.4m following phase 3 data presentation at ASH

Nasdaq-listed Prothena, a late-stage clinical biotechnology company, has priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the public of US$56.50 per share. All of the ordinary shares in the offering were sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to…

You must be a HMI Subscriber to view this content.

Subscribe Now »